Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
United Therapeutics Corp.
Headquarters: Silver Spring, MD, United States of America
Website: http://www.unither.com
Year Founded: 1996
Status: Public
Industry Sector: HealthTechnology
CEO: Martine A. Rothblatt, PhD, MBA
Number Of Employees: 1,305
Enterprise Value: $14,145,740,000
PE Ratio: 11.34
Exchange/Ticker 1: NASDAQ:UTHR
Exchange/Ticker 2: N/A
Latest Market Cap: $12,525,563,904
BioCentury | Oct 31, 2023
Finance
Oct. 30 Quick Takes: VCs pile in for MapLight’s $225M series C
Plus: Deciphera gets lift from TGCT readout and updates from Hengrui, Merck KGaA, AnHeart, Nippon Kayaku, Novartis, GSK and more
BioCentury | Aug 28, 2023
Finance
The expanding universe of public biotechs
Previewing Back to School 2023: Trajectories of public biotechs across market cap tiers — long-term and short-term trends
BioCentury | Jan 31, 2023
Politics, Policy & Law
Jan. 30 Quick Takes: CAFC win for pharmas in 340B case
Plus: Medicines Patent Pool sets goal for growth and Boehringer’s Spevigo meets psoriasis endpoint and updates from Junshi, Simcere and Ribon
BioCentury | Dec 22, 2022
Management Tracks
Genentech bolsters marketing team
Plus: Greene becomes chief investment officer at Hevolution, and updates from Aerami and Curate
BioCentury | Jun 16, 2022
Management Tracks
Dealhoy becomes CBO at Deciphera
Plus new CSO at GlycoEra, and updates from Geron, Ysios, CBC and more
BioCentury | May 25, 2022
Finance
May 24 Quick Takes: Duke Street Bio debuts to develop PARP inhibitors
Plus Alvotech’s Stelara biosimilar demonstrates bioequivalence and updates from uniQure, CSL, Alpine and more
BioCentury | May 5, 2022
Management Tracks
Legault named Egle chairman
Plus Tom Hughes becomes chairman of Totus, and updates from Immunicum, Kbio and more
BioCentury | Feb 25, 2022
Product Development
Feb. 24 Quick Takes: hC Bio enters emerging tRNA field with $24M series A
Plus Abbvie’s Rinvoq meets in Crohn’s; PDUFA date extensions for Tyvaso, Imcivree; Moderna gets KRAS vaccine back; and more
BioCentury | Dec 14, 2021
Deals
With vaccine cash mounting, Pfizer gets IBD therapy via $6.7B Arena buy
Deal sees Arena reap the benefit of its decision to prioritize estrasimod, as Pfizer signals it may not be done buying
Items per page:
1 - 10 of 386